News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alliqua, Inc. (Formerly known as HepaLife Technologies Inc.) (ALQA) Expands Patent Portfolio for Transdermal Drug Delivery Platform


5/4/2011 10:40:53 AM

NEW YORK--(BUSINESS WIRE)--Alliqua, Inc. (OTCBB: ALQA) (FWB: HL1) (“Alliqua” or the “Company”), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office to enhance its transdermal delivery technology. The filing was based on positive test results with respect to specific chemical agents that improved the delivery of active ingredients when used in conjunction with the Company’s hydrogel drug delivery platform. The patent application is directed to specific formulations that management believes will enhance the performance of its platform.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES